ExpreS2ion to participate in upcoming events
Hørsholm, Denmark, 1 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the 2023 BIO International Convention (5-8 June), Aktiespararna’s Small-Cap Day (13 June), and the 2023 Virus-Like Particle & Nano-Particle Vaccines Conference (27-29 June).
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
5-8 June 2023 | 2023 BIO International Convention
Boston, Massachusetts, USA
Meet ExpreS2ion CEO, Bent Frandsen, at the largest global biotechnology industry event. More information and registration can be found on the BIO website.
13 June 2023 | Aktiespararna’s Småbolagsdagarna (Small-Cap Day)
14:45 CET | Stockholm, Sweden
Join CFO Keith Alexander for a live update at Aktiespararna’s Småbolagsdagarna in Stockholm. You can stream the event live or on demand via Aktiespararna’s YouTube channel or aktiespararna.se/tv/live. Read more and register on the Aktiespararna website.
27-29 June 2023 | 2023 Virus-like Particle & Nano-Particle Vaccines Conference
University of Latvia, Riga, Latvia
ExpreS2ion scientists attend the 6th VLPNPV meeting on Virus-Like Particles, the multiprotein structures that mimic native viruses but lack the viral genome, and Nano-Particles, potentially yielding improved vaccine candidates. Read more and register on the MEDICONmm website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.